Format

Send to

Choose Destination
Br J Cancer. 2007 Feb 12;96(3):445-9. Epub 2007 Jan 23.

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

Author information

1
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA. ksmalley@wistar.org

Abstract

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.

PMID:
17245336
PMCID:
PMC2360037
DOI:
10.1038/sj.bjc.6603596
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center